Bracken

CTAs, KOLs, PIs—these acronyms are used in both life sciences and marketing, but they carry different meanings. Want to decode the jargon and stay ahead of the curve? Our marketing services team is here to break it down and keep you informed. Check out our blog to learn more: https://lnkd.in/eH8gXXrv #LifeScienceMarketing #AdvertisingStrategy #LifeSci #IndustryInsights #Bracken

For decades, the main prescription for cancer was chemotherapy. A huge step forward came in the 1990s and 2000s, when more precise therapies arrived. But, while these targeted treatments can be less toxic than chemo, they are usually limited in which cancers they treat. That's where immunotherapies came in. The success of PD1 immunotherapies has set a high standard for treatment — one that, in the years since, drugmakers and researchers have spent billions of dollars trying unsuccessfully to top. This article explores the success of these drugs, but why we might not see its future in new cancer immunotherapies: https://hubs.la/Q02RyLc60 #Immunotherapies #Oncology

What life science podcast are you listening to right now? We've got a recommendation for you. At Bracken, we're proud to bring you Fractals, which features insightful, informative, and warmly good-humored life science conversations. Subscribe to hear life science leaders share wisdom, career highs and lows, and compelling stories from the intersections of clinical development, health care, and technology: https://hubs.la/Q02RyDkL0 #LifeSci #Podcast

What does the future of life sciences look like? That’s just one of the questions Paul Martinetti, MD wants to discuss at the #LifeSciencesSummit tomorrow! Paul is ready to talk innovation, regulatory strategy, and how Bracken’s scalable services—from drug development to business growth, radiopharmaceuticals to marketing, and regulatory to custom analytics—can make you a key player in that future. Don’t miss out! #LifeSciencesSummit #Biotech #ConsultingServices #DataAnalytics #MarketingServices #RegulatoryAffairs #LifeSci #Bracken

Just announced: The FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program is officially approaching its sunset phase. For those involved in regulatory affairs, review your strategy now—the program starts phasing out after December 20, 2024. Our latest blog breaks down the program’s impact and outlines the critical next steps for sponsors. Learn the details and plan for what's ahead: https://lnkd.in/eDmnpY-j #FDA #RareDisease #PRVProgram #FDANews #RegulatoryAffairs #Bracken

In life science, innovation is more than just a buzzword. Bracken’s integrated approach—across concierge-style consulting, regulatory affairs, data-driven marketing, and custom analytics—is designed with that growth in mind. Catch Paul Martinetti, MD at the #LifeSciencesSummit on 10/8 to learn more about how we can support your journey from development to market. Let’s connect! #LifeSciences #RegulatoryAffairs #MarketingServices #DataAnalytics #BiotechGrowth #Networking #Bracken

While 2024 has already hosted some big drug approvals, the year isn’t over yet. Several drug candidates are scheduled for review by the FDA for potential approval in the coming months. This includes novel drugs and indication expansions that could widen the market and offer breakthroughs in different disease areas. Read about the potential blockbusters marching toward FDA review: https://hubs.la/Q02RyjVs0 #FDA #DrugDev

With expertise in pharmacology, due diligence, strategic planning, peptide-based therapeutics, and beyond, it’s no wonder that Bracken co-founder and Managing Partner Dr. James Gilligan is also leading the way in therapeutic psychedelic drug development. With 35+ years of expertise, Jim’s cutting-edge work is reshaping the industry perspective on mental health and chronic pain management. This integrated approach combines clinical insight with scientific innovation, turning psychedelic research into practical, impactful treatments.     In this episode of Fractals, join Jim and host Colin Miller, PhD, FIPEM, CSci as they explore:  • The groundbreaking science behind psilocybin-assisted therapy and its potential to revolutionize mental health and chronic pain treatment, • The essential role of clinical trials in validating psychedelic drugs, and insights into navigating the complex regulatory landscape, • Strategies for biotech startups to attract investors, blending robust clinical data with a compelling commercial strategy, and • How investing in the future of science means supporting areas with high clinical impact, sustainable healthcare solutions, transformative research, and the growth of young scientists.     Listen to Fractals: Life Science Conversations via your preferred podcast service, and subscribe so you never miss an episode: https://lnkd.in/eVxJrpdu   #FractalsLifeScienceConversations #PsychedelicDrugs #DrugDevelopment #FDA #Pharmacology #Psilocybin #LifeSci 

Could your life sciences strategy be missing a key ingredient for success? Paul Martinetti, MD will be at the #LifeSciencesSummit on 10/8 to talk all things life sciences—and how Bracken’s agile solutions and integrated approach can help you succeed. Paul’s ready to answer your questions—let’s connect! #LifeSciencesSummit #Biotech #ConsultingServices #LifeSci #Bracken

Taking psychedelic therapeutics from far out to the forefront of modern medicine—enter Dr. James Gilligan. With over 30 years of experience in pharmacology, due diligence, strategic planning, and peptide-based therapeutics, it's no surprise that Bracken co-founder and Managing Partner Jim Gilligan is also revolutionizing psychedelic drugs for chronic pain and mental health treatment. Tune in to tomorrow's episode of #FractalsLifeScienceConversations to hear more. Subscribe to Fractals now and never miss an episode: https://lnkd.in/gtfzdwSx #FractalsLifeScienceConversations #Psychedelics #PsychedelicTherapeutics #ChronicPain #MentalHealth #Pharmacology #LifeSci #Bracken